Linnea Diep

2.6k total citations · 1 hit paper
11 papers, 1.9k citations indexed

About

Linnea Diep is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Linnea Diep has authored 11 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Oncology. Recurrent topics in Linnea Diep's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Glycosylation and Glycoproteins Research (3 papers) and CAR-T cell therapy research (3 papers). Linnea Diep is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Glycosylation and Glycoproteins Research (3 papers) and CAR-T cell therapy research (3 papers). Linnea Diep collaborates with scholars based in United States and Australia. Linnea Diep's co-authors include Peter Seubert, Jason Goldstein, Robin Barbour, John P. Anderson, Tamie J. Chilcote, Dale Schenk, Rian de Laat, Pamela S. Keim, Xiaofeng Shen and Wei Gai and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and PLoS ONE.

In The Last Decade

Linnea Diep

11 papers receiving 1.9k citations

Hit Papers

Phosphorylation of Ser-129 Is the Dominant Pathological M... 2006 2026 2012 2019 2006 250 500 750 1000

Peers

Linnea Diep
Dong Hwan Ho South Korea
Alice Kaganovich United States
Dawn M. Riddle United States
Terina N. Martinez United States
Haibing Jiang United States
Linnea Diep
Citations per year, relative to Linnea Diep Linnea Diep (= 1×) peers Joakim Bergström

Countries citing papers authored by Linnea Diep

Since Specialization
Citations

This map shows the geographic impact of Linnea Diep's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linnea Diep with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linnea Diep more than expected).

Fields of papers citing papers by Linnea Diep

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linnea Diep. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linnea Diep. The network helps show where Linnea Diep may publish in the future.

Co-authorship network of co-authors of Linnea Diep

This figure shows the co-authorship network connecting the top 25 collaborators of Linnea Diep. A scholar is included among the top collaborators of Linnea Diep based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linnea Diep. Linnea Diep is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Boustany, Leila M., Sherry L. LaPorte, Joel Shen, et al.. (2022). A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Cancer Research. 82(22). 4288–4298. 35 indexed citations
2.
Scolan, Erwan Le, Tiffany Tse, Michael Krimm, et al.. (2019). Abstract 3202: A probody drug conjugate targeting CD166 (ALCAM) enhances preclinical antitumor activity of a probody therapeutic targeting PD-1. Cancer Research. 79(13_Supplement). 3202–3202. 2 indexed citations
3.
Boustany, Leila M., Linnea Diep, Yuanhui Huang, et al.. (2018). Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies. Molecular Cancer Therapeutics. 17(1_Supplement). A164–A164. 25 indexed citations
4.
Singh, Shweta, Jason Sagert, Michael Krimm, et al.. (2016). Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas. Cancer Research. 76(14_Supplement). 2975–2975. 5 indexed citations
5.
LaPorte, Sherry L., Daniel R. Hostetter, Linnea Diep, et al.. (2015). Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies. Molecular Cancer Therapeutics. 14(12_Supplement_2). A203–A203. 1 indexed citations
6.
Feinberg, H., José W. Saldanha, Linnea Diep, et al.. (2014). Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimer s Research & Therapy. 6(3). 31–31. 35 indexed citations
7.
Regnström, Karin, Jiangli Yan, Lan K. Nguyen, et al.. (2013). Label Free Fragment Screening Using Surface Plasmon Resonance as a Tool for Fragment Finding – Analyzing Parkin, a Difficult CNS Target. PLoS ONE. 8(7). e66879–e66879. 16 indexed citations
8.
Motter, Ruth, Armanda Rodrigues, Linnea Diep, et al.. (2013). Development of an enzyme-linked immunosorbent assay (ELISA) to measure the level of tyrosine hydroxylase protein in brain tissue from Parkinson's disease models. Journal of Neuroscience Methods. 215(2). 245–257. 13 indexed citations
9.
Riley, Brigit E., Julie C. Lougheed, Kari Callaway, et al.. (2013). Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nature Communications. 4(1). 1982–1982. 290 indexed citations
10.
Barbour, Robin, John P. Anderson, Tracy Cole, et al.. (2008). Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. Neurodegenerative Diseases. 5(2). 55–59. 393 indexed citations
11.
Anderson, John P., Donald E. Walker, Jason Goldstein, et al.. (2006). Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease. Journal of Biological Chemistry. 281(40). 29739–29752. 1088 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026